ZA200400830B - Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals. - Google Patents
Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals. Download PDFInfo
- Publication number
- ZA200400830B ZA200400830B ZA200400830A ZA200400830A ZA200400830B ZA 200400830 B ZA200400830 B ZA 200400830B ZA 200400830 A ZA200400830 A ZA 200400830A ZA 200400830 A ZA200400830 A ZA 200400830A ZA 200400830 B ZA200400830 B ZA 200400830B
- Authority
- ZA
- South Africa
- Prior art keywords
- formulation
- phosphatidylserine
- stress
- creatine
- lyso
- Prior art date
Links
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 title claims description 68
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 title claims description 68
- 239000000203 mixture Substances 0.000 title claims description 51
- 238000009472 formulation Methods 0.000 title claims description 41
- 241001465754 Metazoa Species 0.000 title claims description 5
- 238000011282 treatment Methods 0.000 title description 7
- 230000002265 prevention Effects 0.000 title description 6
- 230000035882 stress Effects 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 22
- 101800000414 Corticotropin Proteins 0.000 claims description 14
- 210000004556 brain Anatomy 0.000 claims description 14
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 14
- 229960000258 corticotropin Drugs 0.000 claims description 14
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 241000196324 Embryophyta Species 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 230000003340 mental effect Effects 0.000 claims description 10
- 208000014311 Cushing syndrome Diseases 0.000 claims description 9
- 206010049119 Emotional distress Diseases 0.000 claims description 9
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 9
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 244000068988 Glycine max Species 0.000 claims description 7
- 235000010469 Glycine max Nutrition 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- MBBREGJRSROLGD-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound NC(=N)N(C)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MBBREGJRSROLGD-UHFFFAOYSA-N 0.000 claims description 6
- 229960003624 creatine Drugs 0.000 claims description 6
- 239000006046 creatine Substances 0.000 claims description 6
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 230000009429 distress Effects 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 claims description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 5
- 240000006079 Schisandra chinensis Species 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- DLNGCCQFGNSBOP-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.NC(=N)N(C)CC(O)=O DLNGCCQFGNSBOP-UHFFFAOYSA-N 0.000 claims description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 4
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 210000004100 adrenal gland Anatomy 0.000 claims description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 4
- 235000008434 ginseng Nutrition 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 4
- 239000002858 neurotransmitter agent Substances 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 241000218671 Ephedra Species 0.000 claims description 3
- 244000194101 Ginkgo biloba Species 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 3
- 244000141009 Hypericum perforatum Species 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 235000011925 Passiflora alata Nutrition 0.000 claims description 3
- 235000000370 Passiflora edulis Nutrition 0.000 claims description 3
- 235000011922 Passiflora incarnata Nutrition 0.000 claims description 3
- 240000002690 Passiflora mixta Species 0.000 claims description 3
- 235000013750 Passiflora mixta Nutrition 0.000 claims description 3
- 235000013731 Passiflora van volxemii Nutrition 0.000 claims description 3
- 241001165494 Rhodiola Species 0.000 claims description 3
- 241000124033 Salix Species 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- -1 carnithin Chemical compound 0.000 claims description 3
- 235000013601 eggs Nutrition 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 229960001153 serine Drugs 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 claims description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 2
- 240000002234 Allium sativum Species 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010002869 Anxiety symptoms Diseases 0.000 claims description 2
- 206010065369 Burnout syndrome Diseases 0.000 claims description 2
- 240000008397 Ganoderma lucidum Species 0.000 claims description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000019914 Mental Fatigue Diseases 0.000 claims description 2
- 206010028347 Muscle twitching Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 240000003444 Paullinia cupana Species 0.000 claims description 2
- 235000000556 Paullinia cupana Nutrition 0.000 claims description 2
- 235000016787 Piper methysticum Nutrition 0.000 claims description 2
- 240000005546 Piper methysticum Species 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 244000126014 Valeriana officinalis Species 0.000 claims description 2
- 235000013832 Valeriana officinalis Nutrition 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- 229960004826 creatine monohydrate Drugs 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 230000001079 digestive effect Effects 0.000 claims description 2
- 230000003292 diminished effect Effects 0.000 claims description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 229960004756 ethanol Drugs 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
- 235000004611 garlic Nutrition 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 2
- 229960003987 melatonin Drugs 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 229960005190 phenylalanine Drugs 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000036299 sexual function Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 235000000053 special nutrition Nutrition 0.000 claims description 2
- 239000000021 stimulant Substances 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- 229940026510 theanine Drugs 0.000 claims description 2
- 239000011573 trace mineral Substances 0.000 claims description 2
- 235000013619 trace mineral Nutrition 0.000 claims description 2
- 229960004441 tyrosine Drugs 0.000 claims description 2
- 235000016788 valerian Nutrition 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 11
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 11
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 11
- 229960004544 cortisone Drugs 0.000 description 11
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000009469 supplementation Effects 0.000 description 7
- 240000005373 Panax quinquefolius Species 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 210000004720 cerebrum Anatomy 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000008092 positive effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010062767 Hypophysitis Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000002438 stress hormone Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 244000042430 Rhodiola rosea Species 0.000 description 3
- 235000003713 Rhodiola rosea Nutrition 0.000 description 3
- 206010042209 Stress Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000003635 pituitary gland Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000003222 Helianthus annuus Nutrition 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 241000093727 Berzelia alopecuroides Species 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000006618 Paine syndrome Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000241627 Pfaffia Species 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 235000011552 Rhamnus crocea Nutrition 0.000 description 1
- 241000225041 Roestes Species 0.000 description 1
- 241001278097 Salix alba Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010043268 Tension Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 238000003920 environmental process Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000009907 neuroendocrine response Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical group C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000012496 stress study Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
Description
<
Formulation containing (lyso-)phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals
The present invention concerns a formulation containing phosphatidylserine (PS) and/or lyso-phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals.
Stress is a state of the organism which is characterized by a specific syndrome (increased sympathetic activity, increased secretion of catecholamines, elevated blood pressure etc.) and can be triggered by a variety of unspecific stimuli (infections, injuries, burns, radiation effects and also anger, joy, pressure to perform and other factors). Stress can also be understood as external influences to which the body is not adequately adapted e.g. operations, poisoning, pregnancy (anon.,
Pschyrembel — “Klinisches Worterbuch, 1990, Walter de Gruyter, Berlin-New York (1990).
Stress can generally be described as environmental processes which trigger processes in the body through perceptual impulses where eustress is understood as excitatory influences having a positive effect and distress is understood as destructive influences having a negative effect.
Humans react to distress with headaches, sleeplessness, heart complaints, gastric complaints, diarrhoea, skin irritation, allergies, tenseness and/or cramps. Typical psychic stress reactions are nervous unrest, irritability, lack of concentration and sleep disorders. The stress hormones cortisone and ACTH (adrenocorticotrophic hormone) are mainly responsible for these reactions.
Cortisone is formed in the adrenal glands which are two endocrine glands located slightly above the kidneys but fulfil completely different functions to the kidneys.
Cortisone is one of the most important hormones of the body and its absence leads to death within a short period. The main effects of cortisone are: . mobilization of energy reserves in stress states such as disease, operation, physical exertion . maintenance of blood pressure and cardiovascular functions . influences on the inflammatory reactions of the body in the case of infections and chronic inflammatory diseases . regulation of protein, sugar and fat metabolism.
The formation of cortisone is precisely regulated by the body to enable a production according to needs. The pituitary gland (hypophysis) which is a bean-sized structure below the cerebrum and about 6 cm behind the eyes, plays an important role in this regulation. The regulatory hormone (regulatory messenger substance) ACTH is formed in this gland and induces the release of cortisone in the adrenal glands via the blood stream.
Inundation of the body with cortisone may have several causes. A frequent cause is long-term treatment with drugs containing cortisone for inflammatory diseases such as rheumatoid arthritis and bronchial asthma. These are cases of an unavoidable drug side effect which disappears after the patients stop taking the drugs.
Chronically elevated levels of stress hormones can lead to a reduction in lean body mass and suppression of the immune system, and may also result in lethargy followed by a deterioration of physical functions (bone and muscle degeneration).
The damaging effects resulting from the overproduction of stress hormones have already been intensively investigated. They include type II diabetes mellitus, obesity, depression and Cushing’s syndrome.
Cushing’s syndrome is caused by a persistent and excessive formation of the hormone cortisone, the sequelae of which were first described as a disease in 1909 by the doctor Harvey Cushing. 70 % of all cases of Cushing’s syndrome are caused by benign tumours (adenomas) of the pituitary gland which form too much ACTH.
This form of Cushing’s syndrome is also referred to as central Cushing’s syndrome or Morbus Cushing (Cushing’s disease) and affects women 5 x more frequently than men. In 15 % of all patients with Cushing’s syndrome a tumour which forms ACTH is present outside (ectopic) the pituitary gland. These tumours which can also be malignant, are often found in the lung but they can also be located in the thyroid gland, in the thymus or in the pancreas. In 15 % of all cases, benign or malignant adrenal tumours lead to Cushing’s syndrome due to the excessive production of cortisone.
Distress may also cause diabetes mellitus. One study showed that of over 2200 patients between 50 and 74 years, 5 % were newly diagnosed with diabetes mellitus within three years and there was a dependency on the number of stress experiences which not only related to work strain but also to serious events in their lives over the last five years. This relationship was still detectable when the influences of family, alcohol consumption and physical activity were taken into consideration.
Stress has a major influence on the potential functional capacity of the brain. Stimuli are processed in very special regions of the brain. The centres responsible for movements of the body as well as for speech, vision and hearing are located in the cortical fields of the cerebrum which is also the seat of consciousness, will, intelligence, memory and learning ability. This region is also responsible for our personality and character. The cerebellum is responsible for the correct sequence of all movements of the body and also enables orientation in space. The interbrain controls vital vegetative functions such as heat, water and energy regulation and is located between the cerebellum and cerebrum. The frontal cerebrum is apparently particularly important for the development of consciousness which distinguishes humans from most other living organisms. It is assumed that humans are actually aware of only a small part of the information arriving at the frontal cerebrum and that parts of the hindbrain are more likely to be involved especially in the case of emotional strain and stress. In order to stimulate the frontal cerebrum we have to consciously decide to “make the decision” i.e. a deliberate associative thinking.
The ability of humans to learn at any age depends not least on their stress level and their stress tolerance. Enormous stress situations such as examination situations during school or university education can even lead to a complete failure (black out) of brain performance.
Numerous examples of forms of treatment and therapy are known from the literature which are based on the use of phospholipids or formulations which contain phospholipids among others and are supposed to result in improvements in the central nervous system.
Phospholipids which comprise about 75 % of the composition of cell membranes play an extremely important role in connection with the functions of cell membranes by ensuring, among others, the intercellular exchange of information by means of neurotransmitters.
The group of phospholipids is composed of sphingolipids and phosphoglycerides, an important member of the latter being phosphatidylserine.
Phosphatidylserine occurs in the brain in naturally elevated concentrations where it has a positive influence on the extremely sensitive functions of nerve cells and the cells with which they are associated.
As a food supplement phosphatidylserine, like the other phospholipids, does not only have a direct favourable effect on health. Phosphatidylserine can likewise improve the uptake of numerous other foods or food supplements or art synergistically, together with these substances. This was demonstrated in numerous clinical double blind studies.
Furthermore it is known that phosphatidylserine supports the brain in the generation of energy, has a favourable effect on cell/cell connections (synapses), amplifies the effect of chemical transmitter substances such as acetylcholine, dopamine and noradrenalin and serotonin resulting in an improved cognitive capacity of the brain such as concentration, learning ability, short-term memory and remembering words and thus counteracts the natural loss of brain capacity in old age.
Thus WO 99/37155 describes the use of combinations of tyrosine, methylating agents, phospholipids such as phosphatidylserine, fatty acids and active substances of the Evening Primrose in mental disorders. The effect is aimed at strengthening the central nervous system (CNS) where the aim is to redress age-related neurochemical deficits in the form of premature deactivation of neurotransmitters in the CNS by increasing the dopamine and serotonin level. The claimed effect was exemplified by results in elderly human test persons between 48 and 65 years.
In addition there is also the laid-open specification DE 199 43 198 which also suggests the use of plant phosphatidylserine but only in combination with a large amount of docosahexaenic acid as a therapeutic agent for functional disorders of the central nervous system.
The two US patents 5,900,409 and 6,117,853 indicate that PS can be used as a so- called cerebration improver i.e. to improve mental reflection and memory power in dementia and Morbus Parkinson.
Thus the use of phosphatidylserine as a therapeutic agent or food supplement is sufficiently well-known. Also its effect in connection with disorders in the area of the
CNS and in this case only in older persons and the administration of PS from bovine brain in connection with stress studies in the field of sports has also been previously described. However, no improvements were observed under PS supplementation in persons under 40 years and in persons whose brain function was average for their age.
F. Drago et al. describe the protective effect of phosphatidylserine in stress-induced behaviour in old rats (Neurobiology of Aging 12 (5), 437-440, 1991) which was supposed to have been exhibited especially by a normalization of body temperature.
Phosphatidylserine is also claimed to have had a positive effect in lesions of the stomach wall which was, however, only demonstrated for older rats; this effect was not observed in young rats.
Phosphatidylserine has been described to have a protective effect against muscle damage in Nutrition Science News vol. 5, No. 9, September 2000 according to which trained runners received 300 or 600 mg PS per day over 15 days in a study.
Up to recently phosphatidylserine could only be extracted in commercial amounts from bovine brain. When administered in large amounts (800 mg per day) it was shown that bovine brain phosphatidylserine administered orally was able to reduce the increase in cortisone and ACTH in physical stress induced by intensive cycle training (P. Monteleone et al., Blunting by chronic phosphatidylserine administration of stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men,
Eur. J. Clin. Pharmacol. 42, 385-388, 1992; P. Monteleone et al., Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans,
Neuroendocrinology, 52, 243-248, 1990).
Whereas the said results refer to PS from bovine brain sources, E.R. Burke and T.D.
Fahey in “Phosphatidylserine (PS): Promise for Athletic Performance” (Keats
Publishing, Inc., USA; 2001) describe, among others, the effects of soybean PS on physical stress (PS: The Supplement to Help you Adjust to the Stress of Hard
Training).
In “The Influence of Phosphatidylserine Supplementation on Mood and Heart Rate when Faced with an Acute Stressor” (Nutritional Neuroscience, vol. 4, p. 169 — 178, 2001) D. Benton et al. describe the positive effect of 300 mg PS per day in young adults on subjective stress sensitivity, pulse rate and mood.
Extracts and essences of plant origin are also known from numerous publications and well-known commercial preparations which are claimed to alleviate or even prevent typical stress symptoms. The most well-known of these are Gingko biloba, Kava-
Kava, St. John’s wort and Ginseng, belonging to the longest known medical plants.
Extracts from Rhodiola rosea are also known which is a well-known plant of traditional medicine in East Europe and Asia that is claimed to have an effect on the nervous system, an anti-depressive activity and is said to improve physical fitness.
Rhodiola rosea was examined in particular by Russian scientists who have ascribed it an adaptogenic effect. Ginseng species have also be claimed to have stress-alleviating properties which is especially the case for the so-called American, Siberian, Korean and Mandschurian Ginseng species.
Schisandra species whose common name is Wu-Wei-Zi (Schisandra chinensis) usually occur as a woody vine in northern and north-eastern China and the bordering regions of Russia and Korea. The fully ripe, sun-dried red berries are used medicinally for symptoms of tiredness, hepatitis, infectious diseases, to support the liver and also for stress symptoms. Numerous active ingredients have also been discovered in Suma or Para toda which is the dried root of Pfaffia panicolata which is a plant that occurs in the Atlantic rainforest of Brazil. This south American plant which is known as “Brazilian Ginseng” is also considered to be an adaptogen since it can strengthen the immune system and can have positive effects in the case of pain and chronic fatigue syndromes. Furthermore this plant is claimed to accelerate wound healing.
According to “Your Guide to Standardized Herbal Products” by R. Flynn and M.
Roest (Oneworld Press 1995) stress-related effects have also been ascribed to camomile, the willow (Salix alba), the passion flower and certain species of Ephedra (especially Ma Huang) in addition to the above-mentioned plants.
Thus the object of the present invention was to provide a formulation that can be easily dosed for use in the treatment or prevention of stress states in warm-blooded animals, is readily absorbed and does not develop any negative side effects and is based on the known effect of phosphatidylserine.
This object is achieved by a formulation which, in addition to phosphatidylserine (PS) and/or lyso-phosphatidylserine, contains as further active components an active substance from Rhodiola, Ginseng, Schisandra, Suma, camomile, Salix, Ephedra, passion-flower, Gingko, Kava-Kava, St. John’s wort, valerian, garlic, Reishi mushrooms and/or guarana, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, taurine, serine, choline, carnithin, phenylalanine, melatonin, tyrosine, theanine, ethanol, creatine citrate, creatine pyruvate, barbituric acid (derivatives) and any mixtures thereof.
The present invention encompasses all compounds that belong to the phosphatidyl- serine class of substances such as phosphatidyl-L-serine or lyso-phosphatidyl-L- serine as well as physiologically tolerated salts thereof such as phosphates and alkaline (earth) compounds which in this connection are abbreviated to phosphatidylserine or PS. All the other said phospholipids fall in an analogous manner under this definition.
en EE
The proportion of PS relative to other active components is preferably 99:1 to 1:99 wt-%/wt-%, more preferably 95:5 to 5:95 wt-%/wt-% and most preferably 90:10 to 10:90 wt-%/wt-%.
Surprisingly with the formulation according to the invention it was found that the known good tolerance of PS is also now found when administering high doses and over a relatively long supplementation period and that there were no problems with compliance and also no addictive effects occurred in test persons with stress-related problems. Moreover there was a considerable and persistent improvement in typical distress symptoms to an extent that was not to be expected.
When using PS-containing formulations according to the invention it turned out that especially PS exhibited its positive effects particularly well when it is obtained from plant sources, preferably soybean and also from milk or eggs; lecithin-containing oils from rape and sunflowers are also suitable as plant sources. A formulation is also preferred in which the PS has been obtained by transphosphatidylation i.e. by a so- called head group exchange that is usually carried out enzymatically or it may be obtained synthetically. In this case the transphosphatidylation is usually carried out on lecithins that occur in the said vegetable oils of for example rape, soybean and sunflower and also in eggs. It is preferable to use PS from sources other than bovine brain.
Within the scope of the present invention the term starting material is not only to be understood in the sense that it actually contains phosphatidylserine but also that the starting material contains substances such as lecithins from which PS can be obtained enzymatically or also synthetically.
In the present context it has also proven to be very advantageous when the phosphatidylserine is administered in daily doses of 50 to 1000 mg, where 200 to 600 mg are preferred. The respective daily amount is of course dependent on body indices such as size and weight especially in the case of children and juveniles and also depends on whether PS is used for prevention or for an acute treatment.
It is preferred when the claimed formulation, in addition to the essential components according to the invention (lyso) phosphatidylserine and the other active components, contains other components with a stress-preventing or stress-reducing effect such as creatine and suitable derivatives thereof that are different from creatine citrate and creatine pyruvate, vitamins of the B and C series and docosahexaenoic acid and mixtures thereof.
In this case the optional creatine component can be present as creatine monohydrate, another creatine salt, a creatine-containing compound or mixtures thereof in the claimed formulation where in general the other components are preferably present in amounts of 1.0 to 99.0 wt-% based on the total formulation.
The state of aggregation of the claimed formulation is not limited within wide limits but the liquid and solid form are regarded as being preferred.
Among the long series of suitable physiologically tolerated and/or physiologically effective additives various members of the following series have proven to be very suitable for the formulation according to the invention which is different from lyso (PS) and the other components already mentioned : sugars, alcohols, (un)saturated fatty acids, vitamins, trace elements, amino acids, neurotransmitters, stimulants, compounds that stimulate blood flow and (plant) extracts whereby preferably combinations of phosphatidylserine with already known or other compounds and/or medicaments that are suitable for treating mental distress and have an additive or synergistic effect also of course come into consideration but preferably medicaments which inhibit cortisol formation in the adrenal glands.
Depending on the respective formulation the following are provided by the present invention as particularly suitable formulation adjuvants: carbohydrates (e.g. methyl- cellulose), SiO,, stearates, solubilizers, dyes and flavourings, preservatives and separating agents as well as texturing agents.
In addition to the actual formulation the present invention also concerns its use especially in mental distress and in this case preferably for disorders in concentration power, memory disorders, disorders in the ability to recollect and learn, for reduced mental receptiveness, reduced blood flow in the brain, mental fatigue, mental exhaustion, for anxiety states and symptoms of an ACTH (adrenocorticotrophic hormone) imbalance such as Cushing’s syndrome as well as in mental stress associated with sport activities such as golf, biathlon and chess.
Alternatively or in addition the use of the claimed formulation is claimed for typical symptoms of physical distress such as muscle twitching, neuralgic pain and headache, disorders in physical fitness, circulatory disturbances, diminished digestive processes, disorders in sexual function, disorders of the immune system, disturbed wound healing, symptoms of an ACTH (adrenocorticotrophic hormone) imbalance and physical stress associated with sport activities such as golf.
Especially phosphatidylserine which is an endogenous substance is usually very rapidly and completely metabolized and thus already develops its good effects after a short accumulation time. Nevertheless for stress-related applications it is recommended to use it for a minimum of one week. According to the invention a maximum of six months should be adhered to as an upper limit for the regular use of phosphatidylserine for stress-related applications; after pauses and/or a readjustment of the daily dose the supplementation periods can be repeated several times without problems.
Overall a clientele of test persons has proven to be very suitable for the use according to the invention of combination formulations containing phosphatidylserine for the prevention and treatment of mental and/or physical stress states who are aged between 10 and 50 years and are preferably aged between 20 and 35 years. Of course the formulation according to the invention can also be used at any other age in connection with stress symptoms.
Due to its good physiological tolerability and its significant effect in reducing stress hormones, the formulation containing PS and other active components is very well suited within the scope of the present invention especially as a therapeutic agent and/or food supplement whereby especially in the latter case the dosage can be kept low and the administration can also occur over longer periods which is of particular significance in relation to stress prophylaxis. Moreover the present invention also concerns the use of the formulation in functional foods and/or special nutrition (clinical nutrition).
In the case of solid formulations the following are especially suitable: powder, chewing, sucking and effervescent tablets, dragees and capsules and, in view of the usually young age of the preferred subjects, sweets. In the case of liquid formulations juices and soft drinks have proven to be suitable especially in connection with compliance.
The following examples illustrate the advantages of the present invention.
Examples 1. Use of phosphatidylserine and an extract from Rhodiola rosea in school children (mental stress)
Two school children (age 8 and 12 years; male) were examined in an open pilot study. Their performance was measured by suitable empirical tests. The pupils were supplemented with a mixture of 200 mg PS from soybean and 50 mg of a Rhodiola extract per day over a period of 3 months. A direct comparison with the initial values determined under identical conditions before supplementation showed that there was a significant improvement of the overall school performance, but especially under stress situations such as examinations. 2. Use of PS and an extract from American Ginseng in students (mental stress)
Two students (age 24, male and 28, female) were examined. Their performance was measured by suitable empirical tests. The students were supplemented with a mixture of 200 mg PS from soybean and 50 mg of a Ginseng extract per day over a period of months. A direct comparison with the initial values determined under identical conditions before supplementation showed that there was a significant improvement of performance in general and in particular mental performance, but especially under examination conditions and the subjects both stated that their stress tolerance and poise was subjectively improved. 3. Use of a combination of PS and creatine citrate in golf players (physical and mental stress)
Two golf players (age 32 and 33 years, male) were examined. Their performance was checked by repeated putting within a specified period. The subjects were supplemented with a mixture of 200 mg PS from soybean and 10 g creatine citrate per day over a period of 3 months. A direct comparison with the initial values determined under identical conditions before supplementation showed that there was a significantly increased number of holed balls and the subjects themselves said they had a significantly increased concentrating ability.
The present invention concerns a formulation containing phosphatidylserine (PS) and/or lyso-phosphatidylserine for preventing and treating mental and physical stress states wherein the phosphatidylserine is, among others, combined with plant extracts or essences. Daily doses of 50 to 1000 mg PS are envisaged within the scope of the present invention which are administered over a maximum period of six months.
Preferred subjects are humans of 10 to 50 years of age.
Claims (16)
1. Formulation containing phosphatidylserine (PS) and/or lyso-phosphatidyl- serine for preventing or treating stress states in warm-blooded animals, characterized in that it contains as additional active components an active substance from Rhodiola, Ginseng, Schisandra, Suma, camomile, Salix, Ephedra, passion- flower, Gingko, Kava-Kava, St. John’s wort, valerian, garlic, Reishi mushroom and/or guarana, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, taurine, serine, choline, carnithin, phenylalanine, melatonin, tyrosine, theanine, ethanol, creatine citrate, creatine pyruvate, barbituric acid (derivatives) and any mixtures thereof.
2. Formulation as claimed in claim 1, characterized in that it contains (lyso-)phosphatidylserine from plant sources preferably soybean, or from milk or eggs.
3. Formulation as claimed in one of the claims 1 or 2, characterized in that the (lyso-)phosphatidylserine has been obtained by transphosphatidylation or synthetically.
4. Formulation as claimed in one of the claims 1 to 3, characterized in that it contains (lyso-)phosphatidylserine and/or physiologically tolerated salts thereof in quantities that correspond to a daily dose of 50 to 1000 mg, preferably 200 to 600 mg.
5. Formulation as claimed in one of the claims 1 to 4, characterized in that it contains creatine and suitable derivatives thereof that are different from creatine citrate and creatine pyruvate, vitamins of the B and C series and docosahexaenoic acid and mixtures thereof as additional components with a stress-preventing and/or stress-reducing action.
6. Formulation as claimed in claim 5, characterized in that it contains creatine monohydrate, a creatine salt, a creatine-containing compound or mixtures thereof as the creatine component.
7. Formulation as claimed in one of the claims 5 or 6, characterized in that it contains the additional components in amounts of 1.0 to 99.0 wt-% based on the total formulation.
8. Formulation as claimed in one of the claims 1 to 7 in a solid or liquid form.
0. Formulation as claimed in one of the claims 1 to 8, characterized in that it contains other physiologically tolerated and/or physiologically effective additives and/or formulation adjuvants.
10. Formulation as claimed in claim 9, characterized in that it contains as physiologically tolerated and/or physiologically effective additives, at least one member of the following series which is different from (lyso-)phosphatidylserine and the components of claim 5: sugars, alcohols, fatty acids, vitamins, trace elements, amino acids, neurotransmitters,
stimulants, compounds that stimulate the blood flow, (plant) extracts and/or medicaments preferably medicaments which inhibit cortisol formation in the adrenal glands.
11. Formulation as claimed in one of the claims 9 or 10, characterized in that the formulation contains carbohydrates, SiO,, stearates, solubilizers, dyes and flavourings, preservatives and separating agents as well as texturing agents as formulation adjuvants.
12. Use of the formulation as claimed in one of the claims 1 to 11 for mental distress and in particular for disorders in concentration power, memory disorders, disorders in the ability to recollect and learn, for reduced mental receptiveness, reduced blood flow in the brain, mental fatigue, mental exhaustion, for anxiety states and symptoms of an ACTH (adreno- corticotrophic hormone) imbalance such as Cushing’s syndrome and for mental stress associated with sport activities such as golf, biathlon and chess.
13. Use of the formulation as claimed in one of the claims 1 to 11, for typical symptoms of physical distress such as muscle twitching, neuralgic pain and headaches, disorders in physical fitness, circulatory disturbances, diminished digestive processes, disorders in sexual function, disorders of the immune system, disturbed wound healing, symptoms of an ACTH (adreno- corticotrophic hormone) imbalance and physical stress associated with sport activities such as golf and biathlon.
14. Use as claimed in one of the claims 12 or 13, characterized in that it is administered over a maximum period of six months.
,
15. Use as claimed in one of the claims 12 to 14, characterized in that it is administered to persons aged between 10 and 50 years, preferably aged between 20 and 35 years.
16. Use as claimed in one of the claims 12 to 15 as a therapeutic agent and/or food supplement and/or in functional foods and/or as special nutrition.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10139250A DE10139250A1 (en) | 2001-08-09 | 2001-08-09 | Anti-stress formulations based on (lyso)phosphatidyl serine, contains additives such as ginseng, camomile, serine or choline to improve effectiveness against mental or physical stress symptoms |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200400830B true ZA200400830B (en) | 2004-09-21 |
Family
ID=7694980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200400830A ZA200400830B (en) | 2001-08-09 | 2004-02-02 | Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals. |
Country Status (2)
Country | Link |
---|---|
DE (2) | DE10139250A1 (en) |
ZA (1) | ZA200400830B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005003865A1 (en) * | 2005-01-27 | 2007-05-10 | Bioghurt Biogarde Gmbh & Co. Kg | Oral composition, useful e.g. to enhance brain function, comprises phosphatidylserine and a flavor compound or its precursor |
-
2001
- 2001-08-09 DE DE10139250A patent/DE10139250A1/en not_active Withdrawn
-
2002
- 2002-08-05 DE DE10235760A patent/DE10235760A1/en not_active Withdrawn
-
2004
- 2004-02-02 ZA ZA200400830A patent/ZA200400830B/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE10235760A1 (en) | 2003-03-06 |
DE10139250A1 (en) | 2003-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040234544A1 (en) | Formulation containing (lyso-)phosphatidylserine for the prevention and treatment of stress states in warm blooded animals | |
US10272091B2 (en) | Theacrine-based supplement and method of use thereof | |
US11331363B2 (en) | Phytocomplexes exhibiting multiple, synergistic antioxidant activities useful in foods, dietary supplements, cosmetics and pharmaceutical preparations | |
TWI494103B (en) | Composition for improving sexual wellness | |
Navarra | The encyclopedia of vitamins, minerals, and supplements | |
WO2023009681A1 (en) | Paraxanthine-based caffeine substitute compositions and method of use thereof in slow caffeine metabolizers | |
US20110189319A1 (en) | Lifeforce liquid supplement | |
WO2018112475A1 (en) | Energy compositions and methods | |
RU2449600C1 (en) | Biologically active food additive | |
US20150157672A1 (en) | Kits and methods for sustained weight loss | |
TW201636036A (en) | Composition for preventing, improving or treating burn out syndrome | |
US20220233621A1 (en) | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue | |
ZA200400830B (en) | Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals. | |
CN103156188A (en) | Health food with function of immune regulation and hypoxia tolerance | |
KR100814634B1 (en) | Extract of juglans regia l. and nelumbo nucifera gaertn, and composition for stress-free condition comprising the same | |
US11224589B2 (en) | Compositions for a dietary supplement to improve sleep | |
RU2635373C1 (en) | Biologically active additive for increasing general working ability | |
JP2006348001A (en) | Poor circulation-improving agent and functional food | |
RU2616399C1 (en) | Method for producing biologically active product for adaptive feeding and biologically active product for adaptive feeding | |
Kiran et al. | Punica granatum Juice as an Oral Supplemental Therapeutic: Effect on Hemoglobin and Blood Glucose Levels among Diabetic Patients | |
Tusaie | Overview of complementary/Alternative approaches | |
KR20240057401A (en) | Paraxanthin-based caffeine substitute composition and method of use thereof in slow caffeine metabolizers | |
WO2022169973A1 (en) | Dietary supplement for improving brain performance | |
Sun et al. | 13 Herbal Supplements | |
Rountree | Roundoc Rx: A Functional Medicine Approach to Mood Disorders: Part 2—Nutrients and Herbs to Nourish the Brain |